Skip to main content
Fig. 2 | Trials

Fig. 2

From: A multicentre, patient- and assessor-blinded, non-inferiority, randomised and controlled phase II trial to compare standard and torque teno virus-guided immunosuppression in kidney transplant recipients in the first year after transplantation: TTVguideIT

Fig. 2

Study flow of the TTVguideIT study: Informed consent will be obtained from all consecutive adult recipients of a kidney allograft within the first 2 weeks after transplantation at the inpatient ward, and patients will be enrolled in the screening phase of the study (V−3). Subsequent screening visits will be in months 2 (V−2) and 3 (V−1) after transplantation. If all inclusion criteria are met and no exclusion criteria are present, participants will be enrolled in the clinical trial and randomised in month 4 after transplantation (V1). The TAC dose will be adjusted according to the TTV-guided TAC trough level target or the routine centre TAC trough level target. Participants will visit the outpatient clinic every 6 weeks, following the same procedure up to and including month 12 after transplantation (V2–V6). Follow-up will be performed until month 13 post-transplantation (V7)

Back to article page

Trials

ISSN: 1745-6215